- $89.37m
- $130.90m
- $149.16m
Annual income statement for Neuronetics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 55.3 | 65.2 | 71.3 | 74.9 | 149 |
| Cost of Revenue | |||||
| Gross Profit | 43.7 | 49.7 | 51.7 | 54.2 | 72.3 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 82.9 | 100 | 102 | 114 | 181 |
| Operating Profit | -27.6 | -35.1 | -30.6 | -39 | -31.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -31.2 | -37.2 | -30.2 | -43.7 | -39.1 |
| Net Income After Taxes | -31.2 | -37.2 | -30.2 | -43.7 | -39.1 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -31.2 | -37.2 | -30.2 | -43.7 | -39 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -31.2 | -37.2 | -30.2 | -43.7 | -39 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.17 | -1.36 | -1.05 | -1.11 | -0.591 |